董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas E. Polen | 男 | Chief Executive Officer and Chairman of the Board | 51 | 1730.99万美元 | 34.14 | 2024-07-01 |
| Carrie L. Byington | 男 | Independent Director | 61 | 33.78万美元 | 0.28 | 2024-07-01 |
| Joanne Waldstreicher | 女 | Independent Director | 63 | 11.99万美元 | 0.04 | 2024-07-01 |
| Timothy M. Ring | 男 | Independent Director | 66 | 33.28万美元 | 5.79 | 2024-07-01 |
| Claire M. Fraser Liggett | 女 | Independent Director | 69 | 34.02万美元 | 2.17 | 2024-07-01 |
| Christopher Jones | 男 | Independent Director | 69 | 36.28万美元 | 3.00 | 2024-07-01 |
| Bertram L. Scott | 男 | Independent Director | 73 | 37.28万美元 | 5.13 | 2024-07-01 |
| Jeffrey W. Henderson | 男 | Independent Director | 59 | 35.78万美元 | 0.47 | 2024-07-01 |
| R. Andrew Eckert | 男 | Independent Director | 63 | 36.28万美元 | 0.72 | 2024-07-01 |
| William M. Brown | 男 | Independent Director | 61 | 33.28万美元 | 0.16 | 2024-07-01 |
| Catherine M. Burzik | 女 | Independent Director | 74 | 35.78万美元 | 1.33 | 2024-07-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas E. Polen | 男 | Chief Executive Officer and Chairman of the Board | 51 | 1730.99万美元 | 34.14 | 2024-07-01 |
| Roland Goette | 男 | Executive Vice President and President, EMEA | 62 | 未披露 | 未持股 | 2024-07-01 |
| Antoine Ezell | -- | Executive Vice President, President, North America and Chief Marketing Officer | 55 | 未披露 | 未持股 | 2024-07-01 |
| Christopher J. DelOrefice | -- | Executive Vice President and Chief Financial Officer | 53 | 520.64万美元 | 1.82 | 2024-07-01 |
| Richard Byrd | -- | Executive Vice President and President, Interventional Segment | 57 | 未披露 | 未持股 | 2024-07-01 |
| Michael Garrison | -- | Executive Vice President and President, Medical Segment | 56 | 365.44万美元 | 7.62 | 2024-07-01 |
| Pavan Mocherla | -- | Executive Vice President and President, Greater Asia | 55 | 未披露 | 未持股 | 2024-07-01 |
| Shana Neal | -- | Executive Vice President and Chief People Officer | 59 | 588.71万美元 | 4.06 | 2024-07-01 |
| Michelle Quinn | -- | Executive Vice President and General Counsel | 56 | 未披露 | 未持股 | 2024-07-01 |
| David Shan | -- | Executive Vice President and Chief Integrated Supply Chain Officer | 54 | 未披露 | 未持股 | 2024-07-01 |
董事简历
中英对照 | 中文 | 英文- Thomas E. Polen
-
Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
Thomas E. Polen,is the President, Chief Executive Officer and Chairman of the Board of Becton, Dickinson and Company ("BD"), a publicly traded medical technology company, and has served in this role since April 2021. He previously served as President of BD from 2017 until he was appointed as Chief Executive Officer in January 2020. Mr. Polen began his career at BD in 1999 before transitioning to Baxter Healthcare in 2004, where he led the pharmaceutical manufacturing and services business and served in the role of Vice President of Strategic Marketing. In 2007, he was promoted to General Manager of Baxter's Injectable Pharmaceuticals business. Since re-joining BD in 2009, Mr. Polen has served in a variety of leadership roles, including leading the $12 billion acquisition of CareFusion and the $24 billion acquisition of C.R. Bard, Inc. - Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
- Thomas E. Polen,is the President, Chief Executive Officer and Chairman of the Board of Becton, Dickinson and Company ("BD"), a publicly traded medical technology company, and has served in this role since April 2021. He previously served as President of BD from 2017 until he was appointed as Chief Executive Officer in January 2020. Mr. Polen began his career at BD in 1999 before transitioning to Baxter Healthcare in 2004, where he led the pharmaceutical manufacturing and services business and served in the role of Vice President of Strategic Marketing. In 2007, he was promoted to General Manager of Baxter's Injectable Pharmaceuticals business. Since re-joining BD in 2009, Mr. Polen has served in a variety of leadership roles, including leading the $12 billion acquisition of CareFusion and the $24 billion acquisition of C.R. Bard, Inc.
- Carrie L. Byington
-
Carrie L. Byington，加利福尼亚大学卫生部常务副总裁，自2019以来，是美国最大的公共卫生保健系统。2017年至2019年，曾任德克萨斯A&M大学医学院院长、健康科学高级副校长、德克萨斯A&M系统健康服务副校长。从1995到2016在犹他大学的教师，在多个领导角色，包括主任和首席调查员，犹他大学健康临床和转化科学中心，从2015到2016。
Carrie L. Byington is the Executive Vice President of University of California Health, the largest public academic healthcare system in the United States, since 2019. He served as Dean of the College of Medicine, Senior Vice President for Health Sciences for Texas A&M University, and Vice Chancellor for Health Services for Texas A&M System from 2017 to 2019.From 1995 to 2016, served on the faculty of the University of Utah, serving in multiple leadership roles, including as Director and Principal Investigator, Center for Clinical and Translational Science at University of Utah Health from 2015 to 2016. - Carrie L. Byington，加利福尼亚大学卫生部常务副总裁，自2019以来，是美国最大的公共卫生保健系统。2017年至2019年，曾任德克萨斯A&M大学医学院院长、健康科学高级副校长、德克萨斯A&M系统健康服务副校长。从1995到2016在犹他大学的教师，在多个领导角色，包括主任和首席调查员，犹他大学健康临床和转化科学中心，从2015到2016。
- Carrie L. Byington is the Executive Vice President of University of California Health, the largest public academic healthcare system in the United States, since 2019. He served as Dean of the College of Medicine, Senior Vice President for Health Sciences for Texas A&M University, and Vice Chancellor for Health Services for Texas A&M System from 2017 to 2019.From 1995 to 2016, served on the faculty of the University of Utah, serving in multiple leadership roles, including as Director and Principal Investigator, Center for Clinical and Translational Science at University of Utah Health from 2015 to 2016.
- Joanne Waldstreicher
-
Joanne Waldstreicher，她一直担任Structure Therapeutics公司的董事会成员(2022年12月以来)。自2012年12月起，Waldstreicher博士担任强生公司(NYSE: JNJ)的首席医疗官，自2002年起担任各种职务，包括强生Janssen Pharmaceutical Companies of Johnson & Johnson的亚太医学科学首席医疗官和主管(2011年至2012年)，以及全球药物开发高级副总裁、主管(2007年至2009年)。在加入强生公司之前，Waldstreicher博士在默克研究实验室(Merck research Laboratories)负责内分泌学和代谢临床研究。Waldstreicher博士目前还担任纽约大学医学院(New York University School of Medicine)人口卫生系医学伦理部的附属教员。Waldstreicher博士在纽约城市大学布鲁克林学院获得化学学士学位，并在哈佛医学院获得医学博士学位。
Joanne Waldstreicher,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since December 2012, Dr. Waldstreicher has served as Chief Medical Officer at Johnson & Johnson (NYSE: JNJ), where she has served in various roles since 2002, including Chief Medical Officer & Head, Asia Pacific Medical Science at Janssen Pharmaceutical Companies of Johnson & Johnson from 2011 to 2012 and Senior Vice President, Head, Global Drug Development from 2007 to 2009. Prior to joining Johnson & Johnson, Dr. Waldstreicher oversaw endocrinology and metabolism clinical research at Merck Research Laboratories. Dr. Waldstreicher also currently serves as a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine. Dr. Waldstreicher received her B.A. in Chemistry at City University of New York, Brooklyn College, and her M.D. at Harvard Medical School. - Joanne Waldstreicher，她一直担任Structure Therapeutics公司的董事会成员(2022年12月以来)。自2012年12月起，Waldstreicher博士担任强生公司(NYSE: JNJ)的首席医疗官，自2002年起担任各种职务，包括强生Janssen Pharmaceutical Companies of Johnson & Johnson的亚太医学科学首席医疗官和主管(2011年至2012年)，以及全球药物开发高级副总裁、主管(2007年至2009年)。在加入强生公司之前，Waldstreicher博士在默克研究实验室(Merck research Laboratories)负责内分泌学和代谢临床研究。Waldstreicher博士目前还担任纽约大学医学院(New York University School of Medicine)人口卫生系医学伦理部的附属教员。Waldstreicher博士在纽约城市大学布鲁克林学院获得化学学士学位，并在哈佛医学院获得医学博士学位。
- Joanne Waldstreicher,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since December 2012, Dr. Waldstreicher has served as Chief Medical Officer at Johnson & Johnson (NYSE: JNJ), where she has served in various roles since 2002, including Chief Medical Officer & Head, Asia Pacific Medical Science at Janssen Pharmaceutical Companies of Johnson & Johnson from 2011 to 2012 and Senior Vice President, Head, Global Drug Development from 2007 to 2009. Prior to joining Johnson & Johnson, Dr. Waldstreicher oversaw endocrinology and metabolism clinical research at Merck Research Laboratories. Dr. Waldstreicher also currently serves as a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine. Dr. Waldstreicher received her B.A. in Chemistry at City University of New York, Brooklyn College, and her M.D. at Harvard Medical School.
- Timothy M. Ring
-
Timothy M. Ring担任C. R. Bard公司的董事长和首席执行官。Mr. Ring 自2003年8月担任公司董事长和首席执行官，从1997年4月至2003年8月担任集团总裁，在1993年12月至1997年12月担任集团副总裁，从1992年至1993年担任人力资源总裁。他还担任Quest Diagnostics Incorporated的董事。Mr. Ring为CIT集团有限公司的前董事。Mr. Ring是执行委员会成员。Mr. Ring因其先前在董事会工作超过20年，在C. R. Bard有多种领导经验，包括公司董事长和首席执行官，使得其符合董事会要求。 他此前负责公司的全球导管和专业访问业务。Mr. Ring是 has been instrumental in developing and implementing C. R. Bards目前发展和实施器材战略指导。在加入公司之前，他在Abbott Laboratories收获了人力资源和管理方面的宝贵经验。 Mr. Ring是新泽西州牙医科学及药品大学基金会托管人。他在康奈尔大学获得产业与劳动关系理学学士学位。
Timothy M. Ring,is Quest Diagnostics Incorporated Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India. - Timothy M. Ring担任C. R. Bard公司的董事长和首席执行官。Mr. Ring 自2003年8月担任公司董事长和首席执行官，从1997年4月至2003年8月担任集团总裁，在1993年12月至1997年12月担任集团副总裁，从1992年至1993年担任人力资源总裁。他还担任Quest Diagnostics Incorporated的董事。Mr. Ring为CIT集团有限公司的前董事。Mr. Ring是执行委员会成员。Mr. Ring因其先前在董事会工作超过20年，在C. R. Bard有多种领导经验，包括公司董事长和首席执行官，使得其符合董事会要求。 他此前负责公司的全球导管和专业访问业务。Mr. Ring是 has been instrumental in developing and implementing C. R. Bards目前发展和实施器材战略指导。在加入公司之前，他在Abbott Laboratories收获了人力资源和管理方面的宝贵经验。 Mr. Ring是新泽西州牙医科学及药品大学基金会托管人。他在康奈尔大学获得产业与劳动关系理学学士学位。
- Timothy M. Ring,is Quest Diagnostics Incorporated Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India.
- Claire M. Fraser Liggett
-
Claire M. Fraser Liggett自2006年担任董事。自2007年她担任基因组科学协会董事，马里兰巴尔的摩的马里兰大学医学院教授。从1998年至2007年担任基因组研究协会的总裁和主管，该协会是非盈利的破译分析基因的中心。Dr. Fraser在美国科学院董事会工作。Dr. Fraser因其在传染病和分子诊断方面的著名科学家，脑阔新型诊断的发展和疫苗。
Claire M. Fraser Liggett is the Director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine since 2007. She served as President and Director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies, from 1998 to 2007.Chair of the Board and a Director of the American Association for the Advancement of Science.Previously served as a Director of Ohana Biosciences Inc. - Claire M. Fraser Liggett自2006年担任董事。自2007年她担任基因组科学协会董事，马里兰巴尔的摩的马里兰大学医学院教授。从1998年至2007年担任基因组研究协会的总裁和主管，该协会是非盈利的破译分析基因的中心。Dr. Fraser在美国科学院董事会工作。Dr. Fraser因其在传染病和分子诊断方面的著名科学家，脑阔新型诊断的发展和疫苗。
- Claire M. Fraser Liggett is the Director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine since 2007. She served as President and Director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies, from 1998 to 2007.Chair of the Board and a Director of the American Association for the Advancement of Science.Previously served as a Director of Ohana Biosciences Inc.
- Christopher Jones
-
Christopher Jones自2010年担任董事。Mr. Jones在2001年在JWT Worldwide公司首席执行官 ，该公司是J. Walter Thompson，该公司是国际上市公司。自2002年Mr. Jones担任Motion Equity Partners （前身是 Cognetas 股份有限公司）的运营合伙人和董事，该公司泛欧洲私人抵押资产公司。他自2002年起担任Results国际集团公司非执行董事长。他还担任Pavilion Clinic董事会董事长，Johns Hopkins大学 Bloomberg公共健康学院健康顾问委员会成员。Mr. Jones 基于他成功的职业生涯，作为全球上市公司的领导者为国际前景做出了贡献。他为所在的领域提供了大量的上市、战略、管理专业设备。
Christopher Jones retired as Chief Executive Officer of JWT Worldwide (previously known as J. Walter Thompson), an international marketing firm, in 2001.He is the Chair of the Board of Trustees of The Pew Charitable Trusts and member of the Board of Directors of The Albert and Mary Lasker Foundation.Member of the Health Advisory Board of The Johns Hopkins University Bloomberg School of Public Health. - Christopher Jones自2010年担任董事。Mr. Jones在2001年在JWT Worldwide公司首席执行官 ，该公司是J. Walter Thompson，该公司是国际上市公司。自2002年Mr. Jones担任Motion Equity Partners （前身是 Cognetas 股份有限公司）的运营合伙人和董事，该公司泛欧洲私人抵押资产公司。他自2002年起担任Results国际集团公司非执行董事长。他还担任Pavilion Clinic董事会董事长，Johns Hopkins大学 Bloomberg公共健康学院健康顾问委员会成员。Mr. Jones 基于他成功的职业生涯，作为全球上市公司的领导者为国际前景做出了贡献。他为所在的领域提供了大量的上市、战略、管理专业设备。
- Christopher Jones retired as Chief Executive Officer of JWT Worldwide (previously known as J. Walter Thompson), an international marketing firm, in 2001.He is the Chair of the Board of Trustees of The Pew Charitable Trusts and member of the Board of Directors of The Albert and Mary Lasker Foundation.Member of the Health Advisory Board of The Johns Hopkins University Bloomberg School of Public Health.
- Bertram L. Scott
-
Bertram L. Scott自2002年担任董事。Mr. Scott担任Affinity 健康计划公司的总裁和首席执行官。 他此前从2010年6月至2011年12月担任美国CIGNA公司的金融总裁 。在那之前，Mr. Scott从2000年至2010年担任执行副总裁 ，从2000年至2007年担任TIAA-CREF生命保险公司的总裁和首席执行官。Mr. Scott 还担任AXA Financial有限公司董事。Mr. Scott在他的职业生涯多种行政职务中有很强的战略性、运营性、金融经验。他为公司的管理与商业的运营带来了很多保险和健康保健领域经验。
Bertram L. Scott,2015–2019 Senior Vice President of Population Health and Value Based Care at Novant Health, a leading healthcare provider;2012–2014 President and Chief Executive Officer of Affinity Health Plan, a provider of New York State-sponsored health coverage;2010–2011 President, U.S. Commercial of CIGNA Corporation, a global health services organization;2000–2010 Executive Vice President and Chief Institutional Development and Sales Officer of TIAA-CREF;2000–2007 President and Chief Executive Officer of TIAA-CREF Life Insurance Company. - Bertram L. Scott自2002年担任董事。Mr. Scott担任Affinity 健康计划公司的总裁和首席执行官。 他此前从2010年6月至2011年12月担任美国CIGNA公司的金融总裁 。在那之前，Mr. Scott从2000年至2010年担任执行副总裁 ，从2000年至2007年担任TIAA-CREF生命保险公司的总裁和首席执行官。Mr. Scott 还担任AXA Financial有限公司董事。Mr. Scott在他的职业生涯多种行政职务中有很强的战略性、运营性、金融经验。他为公司的管理与商业的运营带来了很多保险和健康保健领域经验。
- Bertram L. Scott,2015–2019 Senior Vice President of Population Health and Value Based Care at Novant Health, a leading healthcare provider;2012–2014 President and Chief Executive Officer of Affinity Health Plan, a provider of New York State-sponsored health coverage;2010–2011 President, U.S. Commercial of CIGNA Corporation, a global health services organization;2000–2010 Executive Vice President and Chief Institutional Development and Sales Officer of TIAA-CREF;2000–2007 President and Chief Executive Officer of TIAA-CREF Life Insurance Company.
- Jeffrey W. Henderson
-
Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
Jeffrey W. Henderson,has been President of JWH Consulting LLC, a business and investment advisory firm, since January 2018. He served as an Advisory Director to Berkshire Partners LLC, a private equity firm, from September 2015 to December 2019. Mr. Henderson served as Chief Financial Officer of Cardinal Health Inc. from May 2005 to November 2014. Prior to joining Cardinal Health, he held multiple management positions at Eli Lilly including serving as President and General Manager of Eli Lilly Canada, and Controller and Treasurer of Eli Lilly Inc., as well as various management positions with General Motors, including in Great Britain, Singapore, Canada and the U.S.Mr. Henderson holds a B.S. in Electrical Engineering from Kettering University and an M.B.A. from Harvard Business School. - Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
- Jeffrey W. Henderson,has been President of JWH Consulting LLC, a business and investment advisory firm, since January 2018. He served as an Advisory Director to Berkshire Partners LLC, a private equity firm, from September 2015 to December 2019. Mr. Henderson served as Chief Financial Officer of Cardinal Health Inc. from May 2005 to November 2014. Prior to joining Cardinal Health, he held multiple management positions at Eli Lilly including serving as President and General Manager of Eli Lilly Canada, and Controller and Treasurer of Eli Lilly Inc., as well as various management positions with General Motors, including in Great Britain, Singapore, Canada and the U.S.Mr. Henderson holds a B.S. in Electrical Engineering from Kettering University and an M.B.A. from Harvard Business School.
- R. Andrew Eckert
-
R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company. - R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
- R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company.
- William M. Brown
-
William M. Brown担任L3harris Technologies, Inc. 董事会主席、总裁兼首席执行官。Brown先生于2011年11月加入哈里斯公司（Harris），担任总裁兼首席执行官，他于2014年4月被任命为董事会主席。加入哈里斯公司前，Brown先生担任美国联合技术公司（United Technologies Corporation，UTC）的公司战略与发展部的高级副总裁。早些时候，他担任UTC的消防与安全部门的总裁。Brown先生在UTC任职总计达14年，在多个部门担任美国国内外的职位，包括开利公司（Carrier Corporation）的亚太地区运营与开利运输冷冻空调部门。于1997年加入UTC以前，他在麦肯锡咨询公司（McKinsey & Company）担任高级项目经理。他在空气化工产品公司（Air Products and Chemicals, Inc.）担任项目工程师而开启其职业生涯。Brown先生从2011年12月开始担任L3harris Technologies, Inc. 董事。Brown先生担任NYC Foundation的消防部门的董事，并是佛罗里达工艺大学（Florida Polytechnic University）的校董会董事。他是国家安全电信咨询委员会（National Security Telecommunications Advisory Committee）的委员，并是美国——巴西首席执行官论坛（United States-Brazil CEO Forum）的派驻代表。
William M. Brown,Executive Chair of the Board (2021 – 2022) and Chair and Chief Executive Officer (2019 – 2021) of L3Harris Technologies, Inc., successor to Harris Corporation, a global aerospace and defense technology company; President and Chief Executive Officer (2011 – 2019) and Chair (2014 – 2019), Harris Corporation. Various roles at United Technologies Corporation (UTC) (1997 – 2011), including as Senior Vice President, Corporate Strategy and Development (2011), President of UTC's Fire & Security Division (2006 – 2011), additional U.S. and international roles at various divisions including Carrier Corporation's Asia Pacific Operations and the Carrier Transicold division. Senior Engagement Manager McKinsey & Company. Project Engineer, Air Products and Chemicals, Inc.. - William M. Brown担任L3harris Technologies, Inc. 董事会主席、总裁兼首席执行官。Brown先生于2011年11月加入哈里斯公司（Harris），担任总裁兼首席执行官，他于2014年4月被任命为董事会主席。加入哈里斯公司前，Brown先生担任美国联合技术公司（United Technologies Corporation，UTC）的公司战略与发展部的高级副总裁。早些时候，他担任UTC的消防与安全部门的总裁。Brown先生在UTC任职总计达14年，在多个部门担任美国国内外的职位，包括开利公司（Carrier Corporation）的亚太地区运营与开利运输冷冻空调部门。于1997年加入UTC以前，他在麦肯锡咨询公司（McKinsey & Company）担任高级项目经理。他在空气化工产品公司（Air Products and Chemicals, Inc.）担任项目工程师而开启其职业生涯。Brown先生从2011年12月开始担任L3harris Technologies, Inc. 董事。Brown先生担任NYC Foundation的消防部门的董事，并是佛罗里达工艺大学（Florida Polytechnic University）的校董会董事。他是国家安全电信咨询委员会（National Security Telecommunications Advisory Committee）的委员，并是美国——巴西首席执行官论坛（United States-Brazil CEO Forum）的派驻代表。
- William M. Brown,Executive Chair of the Board (2021 – 2022) and Chair and Chief Executive Officer (2019 – 2021) of L3Harris Technologies, Inc., successor to Harris Corporation, a global aerospace and defense technology company; President and Chief Executive Officer (2011 – 2019) and Chair (2014 – 2019), Harris Corporation. Various roles at United Technologies Corporation (UTC) (1997 – 2011), including as Senior Vice President, Corporate Strategy and Development (2011), President of UTC's Fire & Security Division (2006 – 2011), additional U.S. and international roles at various divisions including Carrier Corporation's Asia Pacific Operations and the Carrier Transicold division. Senior Engagement Manager McKinsey & Company. Project Engineer, Air Products and Chemicals, Inc..
- Catherine M. Burzik
-
Catherine M. Burzik，自2006年至2012年1月，她在Kinetic Concepts公司担任总裁和首席执行官。该公司是一家医疗设备公司，致力于伤口护理和再生医学领域的事务，并于2012年1月被出售。她现任美国伤口愈合和组织修复学院（American College of Wound Healing and Tissue Repair）的董事长，达拉斯联邦储备银行（Dallas Federal Reserve Board）圣安东尼奥分行的副董事长，并担任Targeted Technology Fund II的运营合伙人。此前，她曾担任Applied Biosystems公司的总裁，在Ortho-Clinical Diagnostics公司（属于Johnson & Johnson 公司旗下）担任总裁，并在Eastman Kodak公司担任多个高管职务。她曾在Allscripts Healthcare Solutions公司担任董事。
Catherine M. Burzik served as President and Chief Executive Officer of Kinetic Concepts, Inc., a medical device company specializing in the fields of wound care and regenerative medicine, from 2006 until the sale of the company in 2012. She previously served as President of Applied Biosystems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company. - Catherine M. Burzik，自2006年至2012年1月，她在Kinetic Concepts公司担任总裁和首席执行官。该公司是一家医疗设备公司，致力于伤口护理和再生医学领域的事务，并于2012年1月被出售。她现任美国伤口愈合和组织修复学院（American College of Wound Healing and Tissue Repair）的董事长，达拉斯联邦储备银行（Dallas Federal Reserve Board）圣安东尼奥分行的副董事长，并担任Targeted Technology Fund II的运营合伙人。此前，她曾担任Applied Biosystems公司的总裁，在Ortho-Clinical Diagnostics公司（属于Johnson & Johnson 公司旗下）担任总裁，并在Eastman Kodak公司担任多个高管职务。她曾在Allscripts Healthcare Solutions公司担任董事。
- Catherine M. Burzik served as President and Chief Executive Officer of Kinetic Concepts, Inc., a medical device company specializing in the fields of wound care and regenerative medicine, from 2006 until the sale of the company in 2012. She previously served as President of Applied Biosystems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company.
高管简历
中英对照 | 中文 | 英文- Thomas E. Polen
Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
Thomas E. Polen,is the President, Chief Executive Officer and Chairman of the Board of Becton, Dickinson and Company ("BD"), a publicly traded medical technology company, and has served in this role since April 2021. He previously served as President of BD from 2017 until he was appointed as Chief Executive Officer in January 2020. Mr. Polen began his career at BD in 1999 before transitioning to Baxter Healthcare in 2004, where he led the pharmaceutical manufacturing and services business and served in the role of Vice President of Strategic Marketing. In 2007, he was promoted to General Manager of Baxter's Injectable Pharmaceuticals business. Since re-joining BD in 2009, Mr. Polen has served in a variety of leadership roles, including leading the $12 billion acquisition of CareFusion and the $24 billion acquisition of C.R. Bard, Inc.- Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
- Thomas E. Polen,is the President, Chief Executive Officer and Chairman of the Board of Becton, Dickinson and Company ("BD"), a publicly traded medical technology company, and has served in this role since April 2021. He previously served as President of BD from 2017 until he was appointed as Chief Executive Officer in January 2020. Mr. Polen began his career at BD in 1999 before transitioning to Baxter Healthcare in 2004, where he led the pharmaceutical manufacturing and services business and served in the role of Vice President of Strategic Marketing. In 2007, he was promoted to General Manager of Baxter's Injectable Pharmaceuticals business. Since re-joining BD in 2009, Mr. Polen has served in a variety of leadership roles, including leading the $12 billion acquisition of CareFusion and the $24 billion acquisition of C.R. Bard, Inc.
- Roland Goette
Roland Goette自2017年5月以来担任欧洲，中东和非洲地区执行副总裁兼总裁； 2014年10月至2017年5月担任欧洲总裁；在此之前，他是西欧医疗外科系统副总裁兼总经理。
Roland Goette, Executive Vice President and President, EMEA since May 2017; and President, Europe from October 2014 to May 2017.- Roland Goette自2017年5月以来担任欧洲，中东和非洲地区执行副总裁兼总裁； 2014年10月至2017年5月担任欧洲总裁；在此之前，他是西欧医疗外科系统副总裁兼总经理。
- Roland Goette, Executive Vice President and President, EMEA since May 2017; and President, Europe from October 2014 to May 2017.
- Antoine Ezell
Antoine Ezell，自2020年10月起担任北美区总裁；自2020年1月起担任执行副总裁兼首席营销官；2019年1月至2020年1月，Eli Lilly公司负责连接护理和胰岛素的副总裁；在此之前，Eli Lilly公司负责企业能力和解决方案的副总裁；首席营销官，Elanco动物健康中心；Eli Lilly首席客户官。
Antoine Ezell, Executive Vice President, President, North America and Chief Marketing Officer since October 2020; Executive Vice President and Chief Marketing Officer from January 2020 to October 2020; Vice President, Connected Care and Insulins, Eli Lilly and Company from January 2019 to January 2020; and prior thereto, Vice President, Enterprise Capabilities and Solutions, Eli Lilly; Chief Marketing Officer, Elanco Animal Health; and Chief Customer Officer, Eli Lilly.- Antoine Ezell，自2020年10月起担任北美区总裁；自2020年1月起担任执行副总裁兼首席营销官；2019年1月至2020年1月，Eli Lilly公司负责连接护理和胰岛素的副总裁；在此之前，Eli Lilly公司负责企业能力和解决方案的副总裁；首席营销官，Elanco动物健康中心；Eli Lilly首席客户官。
- Antoine Ezell, Executive Vice President, President, North America and Chief Marketing Officer since October 2020; Executive Vice President and Chief Marketing Officer from January 2020 to October 2020; Vice President, Connected Care and Insulins, Eli Lilly and Company from January 2019 to January 2020; and prior thereto, Vice President, Enterprise Capabilities and Solutions, Eli Lilly; Chief Marketing Officer, Elanco Animal Health; and Chief Customer Officer, Eli Lilly.
- Christopher J. DelOrefice
Christopher J. DelOrefice，自2021年9月起担任执行副总裁兼首席财务官；2018年8月至2021年8月，强生公司投资者关系副总裁；2017年6月至2018年8月，强生公司北美医院医疗器械部财务副总裁；2014年3月至2017年6月，强生消费品公司北美财务副总裁。
Christopher J. DelOrefice, Executive Vice President and Chief Financial Officer since September 2021; Vice President, Investor Relations, Johnson & Johnson from August 2018 to September 2021; Chief Financial Officer, North America Hospital Medical Devices, Johnson & Johnson from June 2017 to August 2018; and Vice President, Finance, North America, Johnson & Johnson Consumer, March 2014 to June 2017.- Christopher J. DelOrefice，自2021年9月起担任执行副总裁兼首席财务官；2018年8月至2021年8月，强生公司投资者关系副总裁；2017年6月至2018年8月，强生公司北美医院医疗器械部财务副总裁；2014年3月至2017年6月，强生消费品公司北美财务副总裁。
- Christopher J. DelOrefice, Executive Vice President and Chief Financial Officer since September 2021; Vice President, Investor Relations, Johnson & Johnson from August 2018 to September 2021; Chief Financial Officer, North America Hospital Medical Devices, Johnson & Johnson from June 2017 to August 2018; and Vice President, Finance, North America, Johnson & Johnson Consumer, March 2014 to June 2017.
- Richard Byrd
Richard Byrd，执行副总裁兼介入业务总裁，自2022年9月起至今；2019年3月至2022年9月担任BD给药解决方案全球总裁；2016年12月至2019年2月担任预分析系统全球总裁。
Richard Byrd, Executive Vice President and President, Interventional Segment since September 2022; Worldwide President, BD Medication Delivery Solutions from March 2019 to September 2022; Worldwide President, Preanalytical Systems from December 2016 to February 2019.- Richard Byrd，执行副总裁兼介入业务总裁，自2022年9月起至今；2019年3月至2022年9月担任BD给药解决方案全球总裁；2016年12月至2019年2月担任预分析系统全球总裁。
- Richard Byrd, Executive Vice President and President, Interventional Segment since September 2022; Worldwide President, BD Medication Delivery Solutions from March 2019 to September 2022; Worldwide President, Preanalytical Systems from December 2016 to February 2019.
- Michael Garrison
Michael Garrison，自2022年9月起担任医疗部门执行副总裁兼总裁；2020年3月至2022年9月担任BD药物管理解决方案全球总裁；2018年12月至2020年3月担任BD外科全球总裁；2016年7月至2018年12月担任副总裁兼全球输液系统总经理。
Michael Garrison, Executive Vice President and President, Medical Segment since September 2022; Worldwide President, BD Medication Management Solutions from March 2020 to September 2022; Worldwide President, BD Surgery from December 2018 to March 2020; Vice President and General Manager Worldwide Infusion Systems from July 2016 to December 2018.- Michael Garrison，自2022年9月起担任医疗部门执行副总裁兼总裁；2020年3月至2022年9月担任BD药物管理解决方案全球总裁；2018年12月至2020年3月担任BD外科全球总裁；2016年7月至2018年12月担任副总裁兼全球输液系统总经理。
- Michael Garrison, Executive Vice President and President, Medical Segment since September 2022; Worldwide President, BD Medication Management Solutions from March 2020 to September 2022; Worldwide President, BD Surgery from December 2018 to March 2020; Vice President and General Manager Worldwide Infusion Systems from July 2016 to December 2018.
- Pavan Mocherla
Pavan Mocherla，自2022年7月起担任执行副总裁兼大亚洲区总裁；2017年12月至2022年6月担任南亚地区总经理/董事总经理；2017年8月至2017年12月担任大亚洲区战略创新副总裁。
Pavan Mocherla, Executive Vice President and President, Greater Asia since July 2022; Country General Manager, South Asia/Managing Director from December 2017 to June 2022; Vice President of Strategic Innovation for Greater Asia from August 2017 to December 2017.- Pavan Mocherla，自2022年7月起担任执行副总裁兼大亚洲区总裁；2017年12月至2022年6月担任南亚地区总经理/董事总经理；2017年8月至2017年12月担任大亚洲区战略创新副总裁。
- Pavan Mocherla, Executive Vice President and President, Greater Asia since July 2022; Country General Manager, South Asia/Managing Director from December 2017 to June 2022; Vice President of Strategic Innovation for Greater Asia from August 2017 to December 2017.
- Shana Neal
Shana Neal，自2022年4月起担任执行副总裁兼首席人事官；自2018年4月至2022年3月担任Owens & Minor首席人力资源官；自2017年1月至2018年3月担任BD人力资源高级副总裁。
Shana Neal, Executive Vice President and Chief People Officer since April 2022; Chief Human Resources Officer of Owens & Minor from April 2018 to March 2022; Senior Vice President, Human Resources of BD from January 2017 to March 2018.- Shana Neal，自2022年4月起担任执行副总裁兼首席人事官；自2018年4月至2022年3月担任Owens & Minor首席人力资源官；自2017年1月至2018年3月担任BD人力资源高级副总裁。
- Shana Neal, Executive Vice President and Chief People Officer since April 2022; Chief Human Resources Officer of Owens & Minor from April 2018 to March 2022; Senior Vice President, Human Resources of BD from January 2017 to March 2018.
- Michelle Quinn
Michelle Quinn，自2013年4月起担任执行副总裁兼总法律顾问；从2022年2月到2023年4月，担任高级副总裁、副总法律顾问兼首席道德与合规官；2019年5月至2023年1月，高级副总裁、首席道德与合规官、首席监管顾问；2019年2月至2019年5月担任高级副总裁兼首席合规官；2017年1月至2019年1月，Sandoz Inc.担任北美副总裁兼总法律顾问。
Michelle Quinn,Executive Vice President and General Counsel since April 2023; Senior Vice President, Deputy General Counsel and Chief Ethics and Compliance Officer from February 2022 to April 2023; Senior Vice President, Chief Ethics & Compliance Officer, Chief Regulatory Counsel from May 2019 to January 2023; Senior Vice President, Chief Compliance Officer from February 2019 to May 2019; Vice President, General Counsel of North America of Sandoz Inc. from January 2017 to January 2019.- Michelle Quinn，自2013年4月起担任执行副总裁兼总法律顾问；从2022年2月到2023年4月，担任高级副总裁、副总法律顾问兼首席道德与合规官；2019年5月至2023年1月，高级副总裁、首席道德与合规官、首席监管顾问；2019年2月至2019年5月担任高级副总裁兼首席合规官；2017年1月至2019年1月，Sandoz Inc.担任北美副总裁兼总法律顾问。
- Michelle Quinn,Executive Vice President and General Counsel since April 2023; Senior Vice President, Deputy General Counsel and Chief Ethics and Compliance Officer from February 2022 to April 2023; Senior Vice President, Chief Ethics & Compliance Officer, Chief Regulatory Counsel from May 2019 to January 2023; Senior Vice President, Chief Compliance Officer from February 2019 to May 2019; Vice President, General Counsel of North America of Sandoz Inc. from January 2017 to January 2019.
- David Shan
David Shan，自2023年1月起担任执行副总裁兼首席集成供应链官；从2020年3月到2023年8月担任执行副总裁兼首席质量官；2018年5月至2020年8月担任全球供应链高级副总裁；2017年12月至2018年5月担任全球运营设备高级副总裁。
David Shan,Executive Vice President and Chief Integrated Supply Chain Officer since January 2023; Executive Vice President and Chief Quality Officer from March 2020 to August 2023; Senior Vice President, Global Supply Chain from May 2018 to August 2020; Senior Vice President, Worldwide Operations Devices from December 2017 to May 2018.- David Shan，自2023年1月起担任执行副总裁兼首席集成供应链官；从2020年3月到2023年8月担任执行副总裁兼首席质量官；2018年5月至2020年8月担任全球供应链高级副总裁；2017年12月至2018年5月担任全球运营设备高级副总裁。
- David Shan,Executive Vice President and Chief Integrated Supply Chain Officer since January 2023; Executive Vice President and Chief Quality Officer from March 2020 to August 2023; Senior Vice President, Global Supply Chain from May 2018 to August 2020; Senior Vice President, Worldwide Operations Devices from December 2017 to May 2018.